Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by lonc17on Jun 22, 2023 4:56pm
352 Views
Post# 35510036

Precision Promise

Precision PromiseOkay, this is a big deal. There is tons of informaiton out there re this trial, but the most significant points I can find are these:

1.  I believe the non-profit PanCAN will be funding and running this - ONC has been invited as an extedened arm of the trial and their cost will be supply only. 

2.  Only 175 patients necessary for registration approval. 

3.  We're still years away due to the OS endpoint but today's news is equivalent to a Big Pharma stepping up and partnerning with ONC for pancreatic cancer. 

IMO, we're less than one month away from a complete buyout of ONC by some pharma. 

Good news, congrats.

https://aacrjournals.org/cancerres/article/81/22_Supplement/PO-050/670425/Abstract-PO-050-Precision-Promise-PrP-An-adaptive


<< Previous
Bullboard Posts
Next >>